CAMBRIDGE, MA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE, founded in 2017, is a major nonprofit in the Health Care sector that reported $809.5M in total revenue in fiscal year 2023. Revenue surged 6469% from the prior year, signaling strong growth momentum. The organization ran a surplus of $619.8M, a strong 77% operating margin.
THE GATES MRI ENGAGES DIRECTLY IN THE CONDUCT OF MEDICAL RESEARCH IN CONJUNCTION WITH ONE OR MORE HOSPITALS FOR THE PURPOSE OF ADDRESSING MAJOR CAUSES OF ILLNESS AND DEATH IN LOW-AND LOWER-MIDDLE-INCOME COUNTRIES.
BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE ("GATES MRI") IS ALIGNED WITH THE PURPOSE OF THE BILL & MELINDA GATES FOUNDATION AND GUIDED BY THE VISION THAT EVERY PERSON DESERVES THE OPPORTUNITY TO...
BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE ("GATES MRI") IS ALIGNED WITH THE PURPOSE OF THE BILL & MELINDA GATES FOUNDATION AND GUIDED BY THE VISION THAT EVERY PERSON DESERVES THE OPPORTUNITY TO LEAD A HEALTHY AND PRODUCTIVE LIFE. THE GATES MRI IS DEDICATED TO THE RESEARCH, DEVELOPMENT, AND EFFECTIVE USE OF NOVEL BIOMEDICAL INTERVENTIONS ADDRESSING SUBSTANTIAL GLOBAL HEALTH CONCERNS FOR WHICH THE REQUIRED DEVELOPMENT INVESTMENT BY TRADITIONAL BIOPHARMACEUTICAL ORGANIZATIONS IS LACKING. THE GATES MRI WORKS WITH COLLABORATING PARTNERS AND ORGANIZATIONS, COORDINATING AND DRIVING BIOPHARMACEUTICAL RESEARCH AND DEVELOPMENT ACTIVITIES, INCLUDING PRE-CLINICAL DEVELOPMENT AND CLINICAL DEVELOPMENT. IN ADDITION TO THE TUBERCULOSIS WORK NOTED IN 4(B) THE MRI FOCUSES ON PROGRAMS AIMED AT REDUCING THE BURDEN OF MALARIA, DIARRHEAL DISEASES, AND MATERNAL, NEWBORN, AND CHILD ILLNESSES WORLDWIDE.
THE GATES MRI'S LARGEST PROGRAM AREA FOCUSES ON REDUCING THE BURDEN OF TUBERCULOSIS THROUGH THE RESEARCH AND DEVELOPMENT OF NOVEL THERAPEUTICS AND VACCINE CANDIDATES, INCLUDING THROUGH THE CONDUCT OF...
THE GATES MRI'S LARGEST PROGRAM AREA FOCUSES ON REDUCING THE BURDEN OF TUBERCULOSIS THROUGH THE RESEARCH AND DEVELOPMENT OF NOVEL THERAPEUTICS AND VACCINE CANDIDATES, INCLUDING THROUGH THE CONDUCT OF CLINICAL TRIALS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $809,459,647 | $12,321,803 | +64.7% |
| Expenses | $189,613,154 | $137,217,184 | +0.4% |
| Net Income | $619,846,493 | $-124,895,381 | -6.0% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| TREVOR MUNDEL | DIRECTOR, BOARD CHAIR | 3.00 |
Director
|
$0 | $75,958 | $1,425,164 |
| CAROLYN AINSLIE | DIRECTOR | 2.00 |
Director
|
$0 | $78,876 | $1,055,423 |
| TONI HOOVER | DIRECTOR | 2.00 |
Director
|
$0 | $78,033 | $666,113 |
| GAGANDEEP KANG | DIRECTOR (START 10/18/2023) | 2.00 |
Director
|
$0 | $60,196 | $487,832 |
| HELENE MADONICK | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $983 |
| EMILIO EMINI | CHIEF EXECUTIVE OFFICER | 40.00 |
Officer
|
$825,711 | $74,069 | $899,780 |
| MAHENDRA PATTNI | TREASURER (END 11/28/2023) | 40.00 |
Officer
|
$535,156 | $89,346 | $624,502 |
| SALLY JENNINGS | SECRETARY | 40.00 |
Officer
|
$426,910 | $81,699 | $508,609 |
| HARISH KAUSHAL | TREASURER (START 11/28/2023) | 40.00 |
Officer
|
$127,240 | $23,575 | $150,815 |
| MICHAEL DUNNE | CHIEF MEDICAL OFFICER, HEAD OF DEVELOPMENT | 40.00 |
Key Emp
|
$763,134 | $92,474 | $855,608 |
| DEBRA WEISS | CHIEF OPERATING OFFICER | 40.00 |
Key Emp
|
$629,417 | $77,773 | $707,190 |
| PIPER TRELSTAD | HEAD OF CHEMISTRY, MANUFACTURING & CONTROLS | 40.00 |
Key Emp
|
$589,718 | $88,698 | $678,416 |
| JARED SILVERMAN | HEAD OF TRANSLATIONAL DISCOVERY | 40.00 |
Key Emp
|
$509,658 | $90,628 | $600,286 |
| JAMES HULEATT | BIOASSAY DEVELOPMENT LEAD | 40.00 |
Highest
|
$497,303 | $85,390 | $582,693 |
| CHARLES WELLS | HEAD OF THERAPEUTICS DEVELOPMENT | 40.00 |
Highest
|
$496,164 | $76,056 | $572,220 |
| ALEXANDER SCHMIDT | HEAD OF VACCINE DEVELOPMENT | 40.00 |
Highest
|
$479,216 | $90,501 | $569,717 |
| MARLA CURRAN | HEAD OF BIOSTATISTICS & DATA SCIENCE | 40.00 |
Highest
|
$462,582 | $91,298 | $553,880 |
| LUISA STAMM | CLINICAL DEVELOPMENT LEADER | 40.00 |
Highest
|
$463,616 | $86,031 | $549,647 |
| TARYN ROGALSKI-SALTER | HEAD OF GLOBAL REGULATORY STRATEGY | 0.00 |
|
$351,238 | $48,423 | $399,661 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $809,459,647 | $189,613,154 | $816,974,806 | $619,846,493 |
| 2022 | $12,321,803 | $137,217,184 | $186,459,426 | $-124,895,381 |
| 2021 | $216,748,532 | $105,126,022 | $277,647,725 | $111,622,510 |
| 2020 | $32,100,737 | $99,371,314 | $171,367,184 | $-67,270,577 |
| 2019 | $9,807,864 | $41,227,552 | $219,318,998 | $-31,419,688 |
| 2018 | $9,822,484 | $22,373,638 | $248,840,285 | $-12,551,154 |
Compare BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE with other nonprofits in Massachusetts and across the country.